Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute bioavailability study of subcutaneous UCB4940 in healthy volunteers
NL-OMON41792Active, not recruiting
- Sponsor
- UCB
- Start
- Nov 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of bimekizumab in rheumatoid arthritis (RA) and psoriasis (3 arms), sponsored by UCB. Primary endpoint: Absolute bioavailability of single subcutaneous doses of UCB4940. Started Nov 2014; status: active, not recruiting.
02
Drugs
bimekizumab
03
Conditions
rheumatoid arthritis (RA)psoriasis
Beyond the preview
Go deeper on NL-OMON41792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41792.